# PRESS RELEASE 2013

- # [Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific](/content/ferring-pharmaceuticals-appoints-alex-chang-senior-vice-president-asia-pacific/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 01 November 2013  
Ferring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…

- # [MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure](/content/misodel-ferrings-removable-misoprostol-vaginal-delivery-system-approved-for-labour-induction-in-european-decentralised-procedure/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 17 October 2013  
Ferring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…

- # [Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan](/content/ferring-announces-second-3-million-donation-to-the-royal-textile-academy-of-bhutan/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 05 June 2013  
Ferring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…

- # [Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care](/content/ferring-presents-phase-iii-data-for-a-controlled-release-misoprostol-vaginal-delivery-system-for-labour-induction-at-the-first-european-congress-on-intrapartum-care/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 24 May 2013  
Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…

- # [Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation](/content/ferring-pharmaceuticals-begins-phase-iii-trials-of-elobixibat-new-compound-with-novel-mechanism-of-action-for-chronic-idiopathic-constipation/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 02 May 2013  
Ferring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…

- # [Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting](/content/ferring-to-present-safety-analysis-for-firmagon-degarelix-at-the-american-urological-association-annual-meeting/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 01 May 2013  
The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…

- # [New data highlight considerable burden of Nocturia](/content/new-data-highlight-considerable-burden-of-nocturia/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 17 March 2013  
New data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…

- # [Data suggest lower risk of cardiovascular events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists](/content/data-suggest-lower-risk-of-cardiovascular-events-or-deaths-in-prostate-cancer-patients-treated-with-degarelix-compared-to-lhrh-agonists/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 17 March 2013  
Data presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone…

- # [In patients with active, left-sided ulcerative colitis, study shows once-daily dose of mesalazine granules provided similar results to twice-daily dose](/content/in-patients-with-active-left-sided-ulcerative-colitis-study-shows-once-daily-dose-of-mesalazine-granules-provided-similar-results-to-twice-daily-dose/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2013](/content/category/press-release-2013/index.html) on 14 February 2013  
Results of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation…